File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevention of experimental myointimal hyperplasia by immunomodulation

TitlePrevention of experimental myointimal hyperplasia by immunomodulation
Authors
KeywordsImmunotherapy
Myobacterium vaccae
Myointimal hyperplasia
Restenosis
Issue Date2002
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejvs
Citation
European Journal Of Vascular And Endovascular Surgery, 2002, v. 23 n. 1, p. 23-28 How to Cite?
AbstractIntroduction: we have tested the hypothesis that treatment with a mycobacterial preparation that modulates the antibody response, would diminish restenosis in a rat angioplasty model. Materials/Methods: male Sprague-Dawley rats were used. All immunisations were given subcutaneously. Group A (control) received normal saline on days 0, 21, and 42. Group B received SRL172 on days 0, 21, and 42. Group C received SRL172 on days 0, 21, and 42, and hsp65/Incomplete Freund's on days 21 and 42. Group D received hsp65/ Freund's on days 21 and 42. Right common carotid arteries were balloon-injured on day 63 using a standard technique known to produce MIH and animals were sacrificed on day 77. For each carotid 6 μm cross sections were cut from paraffin blocks. Cross-sectional areas were measured by computerised planimetry. Results: balloon injury resulted in MIH in all animals. Data represents mean ± SEM for the percentage of area enclosed within the internal elastic lamina occupied by MIH (% MIH); which for groups A, B, C, and D was 85 ± 11, 24 ± 3, 27 ± 7, and 17 ± 3 respectively. All the treatment groups had significantly less MIH when compared to the control group but no statistically significant difference was found between any of the treatment groups. Conclusions: this is the first report that immunomodulation with mycobacterial material suitable for use in man, can reduce MIH. Since such modulation has low risk, this raises the prospect of an important new therapeutic modality to combat restenosis. © 2002 Harcourt Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/147675
ISSN
2015 Impact Factor: 2.912
2015 SCImago Journal Rankings: 1.723
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorStansby, Gen_HK
dc.contributor.authorChan, YCen_HK
dc.contributor.authorBerwanger, CSen_HK
dc.contributor.authorShurey, Sen_HK
dc.contributor.authorRook, GAWen_HK
dc.contributor.authorStanford, JLen_HK
dc.date.accessioned2012-05-29T06:07:52Z-
dc.date.available2012-05-29T06:07:52Z-
dc.date.issued2002en_HK
dc.identifier.citationEuropean Journal Of Vascular And Endovascular Surgery, 2002, v. 23 n. 1, p. 23-28en_HK
dc.identifier.issn1078-5884en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147675-
dc.description.abstractIntroduction: we have tested the hypothesis that treatment with a mycobacterial preparation that modulates the antibody response, would diminish restenosis in a rat angioplasty model. Materials/Methods: male Sprague-Dawley rats were used. All immunisations were given subcutaneously. Group A (control) received normal saline on days 0, 21, and 42. Group B received SRL172 on days 0, 21, and 42. Group C received SRL172 on days 0, 21, and 42, and hsp65/Incomplete Freund's on days 21 and 42. Group D received hsp65/ Freund's on days 21 and 42. Right common carotid arteries were balloon-injured on day 63 using a standard technique known to produce MIH and animals were sacrificed on day 77. For each carotid 6 μm cross sections were cut from paraffin blocks. Cross-sectional areas were measured by computerised planimetry. Results: balloon injury resulted in MIH in all animals. Data represents mean ± SEM for the percentage of area enclosed within the internal elastic lamina occupied by MIH (% MIH); which for groups A, B, C, and D was 85 ± 11, 24 ± 3, 27 ± 7, and 17 ± 3 respectively. All the treatment groups had significantly less MIH when compared to the control group but no statistically significant difference was found between any of the treatment groups. Conclusions: this is the first report that immunomodulation with mycobacterial material suitable for use in man, can reduce MIH. Since such modulation has low risk, this raises the prospect of an important new therapeutic modality to combat restenosis. © 2002 Harcourt Publishers Ltd.en_HK
dc.languageengen_US
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/ejvsen_HK
dc.relation.ispartofEuropean Journal of Vascular and Endovascular Surgeryen_HK
dc.subjectImmunotherapyen_HK
dc.subjectMyobacterium vaccaeen_HK
dc.subjectMyointimal hyperplasiaen_HK
dc.subjectRestenosisen_HK
dc.subject.meshAdjuvants, Immunologic - Therapeutic Useen_US
dc.subject.meshAngioplasty, Balloonen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntigens, Bacterial - Immunologyen_US
dc.subject.meshBacterial Proteinsen_US
dc.subject.meshBacterial Vaccines - Therapeutic Useen_US
dc.subject.meshCarotid Artery Injuriesen_US
dc.subject.meshCarotid Artery, Common - Pathologyen_US
dc.subject.meshCarotid Stenosis - Pathology - Prevention & Control - Therapyen_US
dc.subject.meshChaperonin 60en_US
dc.subject.meshChaperonins - Immunologyen_US
dc.subject.meshConstriction, Pathologicen_US
dc.subject.meshHyperplasiaen_US
dc.subject.meshMaleen_US
dc.subject.meshMuscle, Smooth, Vascular - Pathologyen_US
dc.subject.meshMycobacterium - Immunologyen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Sprague-Dawleyen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshTunica Intima - Pathologyen_US
dc.subject.meshVaccines, Inactivated - Therapeutic Useen_US
dc.titlePrevention of experimental myointimal hyperplasia by immunomodulationen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, YC: ycchan88@hkucc.hku.hken_HK
dc.identifier.authorityChan, YC=rp00530en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/ejvs.2001.1549en_HK
dc.identifier.pmid11748944-
dc.identifier.scopuseid_2-s2.0-0036134656en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036134656&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue1en_HK
dc.identifier.spage23en_HK
dc.identifier.epage28en_HK
dc.identifier.isiWOS:000173794100005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridStansby, G=7004963829en_HK
dc.identifier.scopusauthoridChan, YC=27170769400en_HK
dc.identifier.scopusauthoridBerwanger, CS=6701673031en_HK
dc.identifier.scopusauthoridShurey, S=6508143053en_HK
dc.identifier.scopusauthoridRook, GAW=7102196411en_HK
dc.identifier.scopusauthoridStanford, JL=7202266598en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats